Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation

Journal of the American Society of Nephrology

Volumn 9, Issue 2, 1998, Pages 224-230

  Ots, Mai ^a   Mackenzie, Harald S ^a,b   Troy, Julia L ^a   Rennke, Helmut G ^a   Brenner, Barry M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PROTEIN; RENIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; KIDNEY INJURY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTECTION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 0031890736     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M, for the New Zealand Hypertension Study Group: Enalapril as first choice treatment of mild, moderate and severe essential hypertension: Results of an open multicenter clinical trial. N Z Med J 100: 137-139, 1987
2. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS: A randomized, placebo-controlled, double-blind parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension (Dallas) 25: 1345-1350, 1995
3. Riegger GA: Lessons from recent randomized controlled trials for the management of congestive heart failure. Am J Cardiol 71: 38E-40E, 1993
4. Lang RM, DiBianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ: First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: A double-blind, randomized, multicenter study - The Enalapril-Captopril Investigators. Am Heart J 128: 551-556, 1994
5. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612-619, 1985
6. Scholey JW, Miller PL, Rennke HG, Meyer TW: Effect of converting enzyme inhibition on the course of Adriamycin-induced nephropathy. Kidney Int 36: 816-822, 1989
7. Zatz R, Dunn BR, Meyer TW, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacologic amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930, 1986
8. Lewis EJ, Hunsicker LG, Bain RP, Rhode RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
9. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118: 577-581, 1993
10. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE: Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant 10: 1963-1974, 1995
11. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P, for The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939-945, 1996
12. Ruff D, Gazdick LP, Herman R, Goldberg AI, Sweet CS: Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens 14: 263-270, 1996
13. Townsend R, Haggert B, Liss C, Edelman JM: Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther 17: 911-923, 1995
14. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90: 766-771, 1992
15. Mackenzie HS, Troy JL, Rennke HG, Brenner BM: TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation. J Hypertens 12[Suppl]: S11-S16, 1994
16. Ziai F, Ots M, Provoost A, Troy J, Rennke H, Brenner BM, Mackenzie HS: The angiotensin receptor antagonist irbesartan reduces renal injury in experimental chronic renal failure. Kidney Int Suppl 50: S132-S136, 1996
17. Iimura O, Shimamoto K: Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I-converting enzyme inhibitors in essential hypertensives. Adv Exp Med Biol 247A: 39-48, 1989
18. Campbell DJ, Kladis A, Duncan AM: Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension (Dallas) 23: 439-449, 1994
19. Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G: Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension (Dallas) 25: 37-46, 1995
20. Campbell DJ, Kladis A, Valentijn AJ: Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 26: 233-240, 1995
21. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241: F85-F93, 1981
22. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993-2000, 1986
23. Slataper R, Vicknair N, Sadler R, Bakris GL: Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 153: 973-980, 1993
24. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118: 129-138, 1993
25. Remuzzi A, Imberti O, Puntorieri S, Malanchini B, Macconi D, Magrini L, Bertani T, Remuzzi G: Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats. Am J Physiol 267: F1034-F1044, 1994
26. Fujiwara Y, Takama T, Shin S, Ochi S, Fukunaga M, Orita Y, Kamada T: Angiotensin stimulates mesangial growth through phosphoinositide cascade [Abstract]. Kidney Int 35: 172, 1989
27. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437, 1994
28. Ketteler M, Noble NA, Border WA: Transforming growth factor-beta and angiotensin II: The missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol 57: 279-295, 1995
29. Farhy RD, Carretero OA, Ho KL, Scicli AG: Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 72: 1202-1210, 1993
30. Carretero O, Polomski C, Scicli A: Role of kinins and nitric oxide in the renal protective effects of ACEI in the subtotal nephrectomy model [Abstract]. Hypertension (Dallas) 22: 415, 1993
31. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205-251, 1993
32. Lo M, Liu KL, Lantelme P, Sassard J: Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. J Clin Invest 95: 1394-1397, 1995
33. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ: The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: Gain-of-function study using gene transfer. Proc Natl Acad Sci USA 92: 10663-10667, 1996
34. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL, Inagami T: Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature (Lond) 377: 748-750, 1995
35. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A: Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 42: 46-55, 1992
36. Sakemi T, Baba N: Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. Nephron 65: 426-432, 1993
37. Brooks D, Contino L, Short B, Gowan C, Trizna W, Edwards R: SB 203220: A novel angiotensin II receptor antagonist and renoprotective agent. J Pharmacol Exp Ther 274: 1222-1227, 1995
38. Imamura A, Mackenzie HS, Lacy ER, Hutchison FN, Fitzgibbon WR, Ploth DW: Effects of chronic treatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats. Kidney Int 47: 1394-1402, 1995
39. Remuzzi A, Malanchini B, Battaglia C, Bertani T, Remuzzi G: Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Exp Nephrol 4: 19-25, 1996
40. Anderson A, Tolbert E, Esparza A, Dworkin L: Effects of an ACE inhibitor (ACEI) vs. an AII antagonist (AA) on hemodynamics, growth, and injury in spontaneously hypertensive rats (SHR) [Abstract]. J Am Soc Nephrol 7: 1849, 1996
41. Benediktsson H, Chea R, Davidoff A, Leendert C: Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Transplantation (Baltimore) 62: 1634-1642, 1996
42. Zoja C, Donadelli R, Corna D, Testa D, Facchinetti D, Maffi R, Luzzana E, Colosio V, Bertani T, Remuzzi G: The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis 29: 254-264, 1997
43. Burdmann EA, Takeshi FA, Nast CC, Evan A, Connors BA, Coffman TM, Lindley J, Bennett WM: Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 269: F491-F499, 1995